课题基金 / 基金详情

MAJOR PSYCHOSES

MAJOR PSYCHOSES
主要精神病
批准号:
2245239
负责人:
HERBERT YALE MELTZER
金额:
$121.06万
依托单位国家:
美国
项目类别:
财政年份:
1985
资助国家:
美国
项目状态:
已结题
起止时间:
1985-09-01 至 1997-08-31

项目摘要

项目成果

HERBERT YALE MELTZER的其他基金

相关文献

中文摘要
翻译
这是一份专门的成熟精神卫生中心(SMH- CRC)。SMH-CRC的主要主题是对 精神分裂症和心境障碍的病理生理学和躯体治疗 与信息丰富的临床前研究相结合。会议的主要目标是 临床前研究是为了探讨其作用机制。 抗精神病和胸腺敏感药物和精神分裂症的动物模型 情绪障碍。SMH-CRC资源向10个国家提供基础设施支持 促进多个SMH-CRC研究的核心实验室 调查人员。这些核心及其主要功能是:1)诊断 和评估核心,其职能是:a)招聘 精神分裂症和情绪障碍患者、相关临床人群和 对参与多个相关方案的正常控制;b) 提供准确、标准化的精神病理学诊断和评估 在短期和长期内;以及c)进行研究或病因学和 精神病理学;2)数据管理、分析和研究设计核心 它提供:a)研究设计咨询;b)数据管理和 审计;c)中央数据库;d)数据分析;3) 精神药理学核心,支持和协调治疗研究 A)精神分裂症,特别是氯氮平的疗效,其他非典型 抗精神病药物和电休克疗法;以及b)情绪和药物治疗的研究 相关人格障碍(边缘性人格障碍,OD); 神经内分泌学核心,支持5-羟色胺的挑战研究 (5-羟色胺和多巴胺(DA)相关药物治疗精神分裂症、情绪障碍、 相关障碍和正常志愿者;5)神经化学核心 支持5-羟色胺能的死后血浆和脑脊液神经化学研究 和多巴胺能神经传递在精神分裂症、情绪障碍和 自杀和药物血浆水平的研究;6)大脑成像核心, 它提供:a)脑结构的CT和MRI测量,以及b)PET 5-羟色胺能和多巴胺能系统及区域的研究 精神分裂症和抑郁症的新陈代谢;7)神经心理学核心, 它们提供了认知功能的测量,特别是记忆功能 精神分裂症;8)支持眼球跟踪的心理生理学核心, 精神分裂症与心境的运动知觉和后向掩蔽研究 精神障碍;9)精神分裂症的神经科学/抗精神病药物核心 这为典型和非典型肺炎作用机理的基础研究提供了支持。 非典型抗精神病药物与精神分裂症病理生理学动物模型 精神分裂症,如慢性抗精神病药物对精神分裂症的影响 神经递质,糖皮质激素在神经毒性中的作用;以及 情绪障碍的神经科学/情绪-支持研究的药物核心 啮齿类动物HPA轴的调节以确定HPA的基础 抑郁症的异常及其发病机制的基础研究 抗抑郁药的作用。SMH-CRC还为以下项目提供试验资金 并促进了以下人员的培训和职业发展 一大批年轻的调查员。
英文摘要
This is an application for a Specialized Mature Mental Health Center (SMH- CRC). The major theme of the SMH-CRC is the longitudinal study of the pathophysiology and somatic treatments of schizophrenia and mood disorders integrated with informative preclinical research. The major aims of the preclinical research are to investigate the mechanism of action of antipsychotic and thymoleptic drugs and animal models of schizophrenia and mood disorder. The SMH-CRC resources provide infrastructure support to ten core laboratories which facilitate the research of multiple SMH-CRC Investigators. These cores and their major functions are: 1) the Diagnosis and Assessment Core, the functions of which are: a) to recruit schizophrenic and mood disorder patients, related clinical populations and normal controls for participation in multiple, related protocols; b)to provide accurate, standardized diagnosis and assessment of psychopathology over the short and long term; and c) to carry out research or nosology and psychopathology; 2) the Data Management, Analysis and Research Design Core which provides: a) consultation on research design; b) data management and audit; c) a central data bank; and, d) data analysis; 3) the Psychopharmacology Core, which supports and coordinates treatment studies in: a) schizophrenia, especially the effect of clozapine, other atypical antipsychotic drugs, and ECT; and b) studies of drug therapy of mood and related personality disorders (borderline personality disorder, OD); 4) the Neuroendocrinology Core, which supports challenge studies with serotonin (5-HT- and dopamine (DA)-related drugs in schizophrenia, mood disorders, related disorders and normal volunteers; 5) the Neurochemistry Core, which supports post-mortem plasma and CSF neurochemical studies of serotonergic and dopaminergic neurotransmission in schizophrenia, mood disorders and suicide as well as drug plasma level studies; 6) the Brain Imaging Core, which provides; a) CT and MRI measures of brain structure, and b) PET studies of the serotonergic and dopaminergic systems and regional metabolism in schizophrenia and depression; 7) the Neuropsychology Core, which provide measures of cognitive, especially memory, function in schizophrenia; 8) the Psychophysiology Core, which supports eye tracking, motion perception and backward masking studies in schizophrenia and mood disorders; 9) the Neuroscience of Schizophrenia/Antipsychotic Drug Core which supports basic research on the mechanism of action f typical and atypical antipsychotic drugs and animal models of the pathophysiology of schizophrenia, e.g. effect of chronic antipsychotic drugs on neurotransmitters, role of glucocorticoids in neurotoxicity; and 10) the Neuroscience of Mood Disorders/Mood-Drug Core which supports research on the regulation of HPA axis in rodents to determine the basis for HPA abnormalities in major depression and basic studies on the mechanism of action of antidepressants. The SMH-CRC also provides pilot funds for Investigations and has facilitated the training and career development of a large cadre of young investigators.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IPSAPIRONE ON PLASMA CORTISOL, PROLACTIN & GROWTH HORMONE IN PSYCHIATRIC ILLNESS
  • 批准号:
    6115654
  • 项目类别:
  • 资助金额:
    $3.64万
  • 财政年份:
    1998
  • 负责人:
    HERBERT YALE MELTZER
  • 依托单位:
IPSAPIRONE ON PLASMA CORTISOL, PROLACTIN & GROWTH HORMONE IN PSYCHIATRIC ILLNESS
  • 批准号:
    6276888
  • 项目类别:
  • 资助金额:
    $3.29万
  • 财政年份:
    1997
  • 负责人:
    HERBERT YALE MELTZER
  • 依托单位:
CORE--NEUROENDOCRINOLOGY AND PHYSIOLOGY
  • 批准号:
    6111353
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    1996
  • 负责人:
    HERBERT YALE MELTZER
  • 依托单位:
EFFECT OF TRAZODONE TO POTENTIATE IMIPRAMINE IN THE TREATMENT OF DEPRESSION
  • 批准号:
    6111340
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    1996
  • 负责人:
    HERBERT YALE MELTZER
  • 依托单位: